Key facts
- Class: synthetic pentadecapeptide (15 amino acids, sequence GEPPPGKPADDAGLV); also called Body Protection Compound 157 and, in its old drug-development files, PL 14736 / PLD-116.
- Origin: derived at the University of Zagreb from a partial sequence of a protein its discoverers identified in human gastric juice.
- Approval status: not approved anywhere. Unapproved investigational compound; no completed, published phase III trial.
- Evidence level: extensive rodent and in-vitro data; three small uncontrolled human pilot reports; zero randomized controlled trials.
- Routes studied: intraperitoneal, subcutaneous, intra-articular, intragastric and topical in animals; injectable and oral products circulate on the gray market.
- Sport: prohibited by WADA under class S0 (non-approved substances) at all times, all routes, since 1 January 2022.
- Reported effects in humans: no controlled safety dataset exists; pilot reports and user accounts describe injection-site reactions and mild transient symptoms.
What is BPC-157?
BPC-157 is a chain of 15 amino acids — GEPPPGKPADDAGLV — synthesized to match part of a larger protein that researchers at the University of Zagreb reported finding in human gastric juice. The abbreviation stands for Body Protection Compound. It is not a hormone, not a growth factor, and not a recognized endogenous signaling molecule with a mapped receptor.
In the 1990s and 2000s the compound carried pharmaceutical development codes — PL-10, PLD-116, PL 14736 — while the Croatian company Pliva pursued it as a treatment for inflammatory bowel disease. Early-phase human work was carried out. Results were never published in a peer-reviewed journal with full data, and the program did not continue. The US Anti-Doping Agency puts it bluntly, describing "a concerning lack of published clinical trial data because studies appear to have been cancelled or stopped without any published conclusions."
What did continue, at volume, was preclinical publishing. Three decades of rodent studies have reported effects on gastric and intestinal lesions, tendon and ligament injury, muscle crush injury, bone defects, corneal wounds, fistulas, and vascular injury. That breadth is unusual, and it is the reason BPC-157 became the most-discussed "healing peptide" on the internet. It is also, as several recent reviews point out, a reason for caution: a compound reported to help almost every tissue in almost every model, largely from a small cluster of research groups, has not been stress-tested the way an approved drug has.
Does BPC-157 actually work?
Split the question in two, because the answers are different.
In animals: the signal is consistent. A 2025 systematic review in HSS Journal screened the orthopaedic literature and identified 36 studies of BPC-157 published between 1993 and 2024 — 35 of them preclinical and exactly one clinical. Across rat models of muscle, tendon, ligament and bone injury, the reviewed studies reported improved healing, better biomechanical strength at the repair site, and reduced inflammatory cytokine expression.
The mechanistic work points the same direction. A 2011 study in the Journal of Applied Physiology found that BPC 157 accelerated outgrowth from rat Achilles tendon explants, improved tendon fibroblast survival under oxidative stress, and increased cell migration dose-dependently via the FAK–paxillin pathway. A 2019 review in Cell and Tissue Research reached similar conclusions about musculoskeletal soft-tissue healing in animal models.
The gastrointestinal literature predates the sports-medicine interest by a decade. Rat work published in the World Journal of Gastroenterology in 2004 reported protection against experimentally induced gastric ulcers, and later reviews summarized rodent models of GI tract injury and NSAID-induced damage. A 2021 Frontiers in Pharmacology review covered skin, burn and diabetic-wound models.
In humans: unknown. Not "probably yes," not "probably no" — unknown, in the specific sense that no trial capable of answering the question has been published. Rodent healing models are notoriously poor predictors of human musculoskeletal outcomes, and drug development is full of compounds that healed rat tendons and then failed in people. That gap between animal promise and human proof is the entire story of BPC-157.
What human evidence exists on BPC-157?
A 2025 narrative review in Current Reviews in Musculoskeletal Medicine — titled, pointedly, "Regeneration or Risk?" — counted the human record: three pilot studies, covering knee pain, interstitial cystitis, and the safety of an intravenous infusion. Not three trials. Three pilots, each small, none randomized, none placebo-controlled, none blinded.
The knee-pain case series
The single clinical study captured by the 2025 systematic review was a retrospective series of patients receiving intra-articular injection for chronic knee pain. As summarized in that review, 7 of 12 patients reported relief lasting more than six months. Retrospective, uncontrolled, telephone follow-up, no imaging endpoint, no placebo arm. It is a hypothesis, not a result.
A 2026 review in the International Journal of Molecular Sciences reached the same verdict, noting that clinical validation "remains limited to small pilot studies" and calling for rigorous controlled trials before any clinical translation. A 2026 primer for orthopaedic physicians in the American Journal of Sports Medicine makes the same point for clinicians fielding patient questions about injectable peptide therapy, and a 2025 Arthroscopy editorial notes that these compounds are freely available online while the outcomes literature stays sparse.
There is also no published human pharmacokinetic profile. The half-life figure that circulates online — under 30 minutes, hepatic metabolism, renal clearance — comes from the animal data summarized in the systematic review, not from a dedicated human PK study.
How is BPC-157 thought to work?
Every proposed mechanism below comes from animal or cell-culture work. None has been confirmed in a human trial.
- Angiogenesis via VEGFR2. The most-cited pathway. Reviews describe BPC-157 activating VEGFR2 signaling and promoting new vessel formation — relevant because tendon and ligament are poorly vascularized, which is part of why they heal slowly.
- Nitric oxide system modulation. Repeatedly invoked across the Zagreb group's cytoprotection work, including vascular and gastric models.
- Fibroblast migration through FAK–paxillin. Demonstrated in cultured rat tendon fibroblasts.
- Growth hormone receptor expression. Reported to increase in tendon fibroblasts, which would sensitize them to circulating GH — a different mechanism than the GH secretagogues, which raise GH itself.
- Cytokine and pain modulation. Reduced inflammatory cytokine activity in injury models, plus reported analgesic effects through peripheral and dopaminergic pathways.
The VEGFR2 story is a double-edged one. Angiogenesis is what makes a poorly perfused tendon repair plausible; angiogenesis is also how tumors build their blood supply. That is the honest basis of the cancer question addressed below — mechanistic concern, not evidence of harm.
Is BPC-157 FDA approved or legal?
BPC-157 is not approved as a drug by the FDA, the EMA, or any other national regulator. It has never been the subject of a completed, published phase III program, which is the standard route to approval for any new molecule (see the general framework in this overview of drug trial phases). It is also not a legal dietary supplement in the United States, because a substance investigated as a drug cannot be marketed as a supplement.
The compounding story is more specific and has moved recently:
- Nomination. BPC-157 was nominated for the FDA's 503A bulk drug substances list, principally for use in ulcerative colitis, so that compounding pharmacies could legally prepare it.
- 2023: Category 2. The FDA placed BPC-157 in Category 2 — bulk substances that "may present significant safety risks." The agency's stated concerns were immunogenicity risk for certain routes of administration, complexity around peptide-related impurities and characterization of the active ingredient, and insufficient safety information for the proposed routes. Compounders could no longer legally use it.
- April 2026: removed from Category 2. BPC-157 was among a group of peptides taken off the Category 2 list, making them eligible for formal reconsideration. This is procedural, not an endorsement.
- July 2026: advisory committee review. The FDA's Pharmacy Compounding Advisory Committee is scheduled to review BPC-157 (free base and acetate are treated as separate nominations) for 503A bulks-list eligibility on 23 July 2026, alongside several other peptides.
Two things worth keeping straight. First, removal from a restricted list is not addition to an approved list, and neither is drug approval — even a favorable committee vote would only mean a compounding pharmacy could legally prepare it under a prescription. Second, none of this changes the evidence base by a single study. The regulatory conversation is about whether the substance may be compounded, not about whether it works.
In practice, most BPC-157 sold online is labeled "for research use only, not for human consumption." That wording is a legal shield for the seller. It carries no guarantee of identity, purity, sterility, or correct peptide content — exactly the impurity and characterization problems the FDA flagged. For a broader treatment of how these categories work, see are peptides legal?
Is BPC-157 banned in sport?
Yes, and unambiguously. The World Anti-Doping Agency named BPC-157 on its Prohibited List effective 1 January 2022, under class S0: non-approved substances. S0 covers pharmacological agents with no current approval by any governmental regulatory health authority for human therapeutic use.
Three consequences follow. S0 substances are prohibited at all times — in competition and out of competition, off-season included. The prohibition is route-agnostic: injectable, oral, nasal and topical products are all covered, so "it was only a capsule" is not a defense. And because there is no approved therapeutic use, a Therapeutic Use Exemption is not realistically available. USADA's own guidance stresses that "because BPC-157 has not been extensively studied in humans, no one knows if there is a safe dose, or if there is any way to use this compound safely."
Contaminated supplements are a real vector here. Testing programs have found BPC-157 in products sold as ordinary wellness supplements, which means a tested athlete can incur a violation without ever intending to take a prohibited peptide.
Oral vs injectable BPC-157: does the oral form do anything?
This is the most contested practical question about the compound, and the honest answer is that no one has published a human head-to-head comparison.
The case for oral rests on a genuinely unusual property: the peptide is described as stable in gastric acid, which is why intragastric administration appears throughout the animal GI literature rather than only injection. Most peptides are destroyed in the stomach, so acid stability is a real point of difference.
The case against is that acid stability solves one barrier out of three. An orally administered peptide must also survive pancreatic and brush-border proteases in the small intestine, and then cross an epithelium that is specifically built to keep large hydrophilic molecules out. As a long-standing review of oral peptide drug delivery sets out, oral bioavailability for unmodified peptides is typically a fraction of one percent without permeation enhancers or protective formulation — which is why the few oral peptide drugs that exist required years of formulation engineering to get there.
What that means in practice: the animal studies that report oral efficacy used defined amounts in rodents with very different gut physiology, and none of it establishes what a human absorbs from a capsule of unknown provenance. Regulators draw no distinction whatsoever — WADA's S0 listing and the FDA's compounding position cover oral, injectable and topical alike. If you are comparing routes generally, our overview of subcutaneous injection sites and rotation covers why route affects absorption and local tolerability.
BPC-157 side effects and the safety unknowns
Two statements are both true and easy to confuse.
Nothing alarming has been reported. Animal toxicity work described in the systematic review found no adverse effects, and the three human pilot reports described no major adverse events. The narrative reviews consistently describe an apparently benign short-term profile.
That is not a safety profile. Absence of reported harm from three uncontrolled pilot studies and a body of rodent work is not the same as demonstrated safety. There is no controlled human trial, therefore no denominator, no standardized adverse-event collection, no laboratory monitoring dataset, and no long-term follow-up. The most common effects described anecdotally — injection-site redness or soreness, transient fatigue, headache, mild nausea with oral products — come from user reports rather than any trial.
The specific open questions are:
- Immunogenicity. The FDA flagged this explicitly for certain routes. Synthetic peptides can provoke antibody responses; nobody has measured this systematically for BPC-157 in people.
- Long-term angiogenic signaling. Chronic stimulation of VEGFR2 pathways has no human safety dataset here, and no study has been designed to detect a tumor-promotion signal.
- Product quality. Gray-market vials carry unverified identity, purity and sterility. Peptide-related impurities were one of the FDA's named concerns.
- Interactions. No published interaction studies with medications, including anticoagulants or immunosuppressants.
BPC-157 vs TB-500, GHK-Cu and thymosin alpha-1
The "repair peptides" are often discussed as one category. Their evidence bases are very different, and the table below compares them on the axis that matters most — what has actually been tested in humans.
| Peptide | What it is | Strongest published evidence | Human RCTs | Regulatory status |
|---|---|---|---|---|
| BPC-157 | Synthetic 15-aa fragment of a gastric juice protein | Large rodent literature on tendon, gut, muscle, wound healing | None published | Unapproved everywhere; WADA S0 since 2022 |
| TB-500 | Synthetic fragment of thymosin beta-4, an actin-binding protein | Thymosin beta-4 itself reached early-phase human trials for corneal and dermal wounds | None for the TB-500 fragment | Unapproved; WADA prohibited |
| GHK-Cu | Naturally occurring human copper-binding tripeptide | Human skin studies; decades of cosmetic use as a topical | Small topical dermatology studies only | Legal in topical cosmetics; injectable form unapproved |
| Thymosin alpha-1 | Naturally occurring 28-aa immunomodulatory peptide | Meta-analyzed randomized data in sepsis; approved in a number of countries | Yes, several | Not FDA approved; approved in some other jurisdictions |
Thymosin beta-4, the parent protein of TB-500, has its own literature as a corneal wound-healing and anti-inflammatory agent. GHK-Cu is the outlier in the group: it is an endogenous human tripeptide with documented tissue-remodeling activity and a long topical track record. And thymosin alpha-1 is the only one of the four with meta-analyzed randomized human data. For a direct head-to-head, see BPC-157 vs TB-500.
How long does BPC-157 take to work?
There is no evidence-based answer, and any specific timeline you see quoted is extrapolated from rodent studies or self-report.
What can be said: the single human case series described relief persisting beyond six months after intra-articular injection, but with no placebo comparison. That last detail is not a technicality. Tendon and ligament injuries improve on their own over weeks to months as part of normal remodeling, and most people trying a recovery peptide are simultaneously changing training load, adding rehab work, and resting the injury. Those confounders are exactly what a control arm exists to strip out, and no BPC-157 study has had one.
So the practical situation is this: if you are working with a clinician who has decided this is appropriate for you, the only way to say anything about your own response is to record it systematically — start date, site, timing, pain and function scores, training load, and everything else that changed at the same time. Without that record, a personal n-of-1 is indistinguishable from natural recovery. That is the case for structured tracking whatever the compound.
Frequently asked questions
Is BPC-157 FDA approved?
No. BPC-157 is not an FDA-approved drug and is not approved by any other national regulator. It has never completed a published phase III trial. It was nominated for the 503A compounding bulks list, placed by the FDA in Category 2 in 2023 over safety and characterization concerns, then removed from Category 2 in April 2026 so it could be formally reconsidered. Removal from a restricted list is not approval.
Does BPC-157 actually work for tendon and ligament injuries?
In rodents, consistently yes. A 2025 systematic review in HSS Journal identified 36 studies of BPC-157 in orthopaedic contexts published between 1993 and 2024, of which 35 were preclinical and only one was clinical. Rat Achilles and ligament models show faster healing and better biomechanical strength. There is no randomized controlled trial in humans, so the effect size in people is unknown.
Is BPC-157 legal to buy?
It is not legal to sell BPC-157 as a dietary supplement or as a drug for human use in the United States, because it is an unapproved drug. Most online sellers list it as a research chemical labeled not for human consumption, which is a liability shield for the vendor rather than a quality guarantee. Rules differ by country, and possession law differs from sale law.
Is oral BPC-157 as good as injectable BPC-157?
Nobody has published a head-to-head human comparison, so the honest answer is that it is unknown. The oral argument rests on the peptide being unusually stable in gastric acid. Acid stability is only the first hurdle: oral peptides must also survive intestinal proteases and cross the gut wall, and oral bioavailability for unmodified peptides is generally very low without an enabling formulation.
What are the side effects of BPC-157?
Animal toxicity studies reported no adverse effects, and the small human pilot reports described no major adverse events. That is not the same as a safety profile. With no controlled human trial there is no denominator, no monitoring data, and no long-term follow-up. Users commonly report injection-site reactions, transient fatigue, headache and nausea, but none of this is confirmed by controlled data.
Is BPC-157 banned in sports?
Yes. The World Anti-Doping Agency added BPC-157 by name to its Prohibited List effective 1 January 2022, under class S0, non-approved substances. S0 substances are prohibited at all times, in and out of competition, and the ban applies to every route including injectable, oral and topical products. A positive test is an anti-doping rule violation.
Does BPC-157 cause cancer?
There is no evidence that BPC-157 causes cancer and no study designed to answer that question. The concern is theoretical and mechanistic: the peptide is described as acting partly through VEGFR2 signaling and angiogenesis, the same pathway tumors use to build blood supply. Without long-term human data, the risk cannot be quantified in either direction.
How long does BPC-157 stay in your system?
The 2025 HSS Journal systematic review describes hepatic metabolism, renal clearance and a plasma half-life under 30 minutes, figures derived from animal work rather than a published human pharmacokinetic study. Anti-doping detection windows are a separate question and depend on the assay, not on plasma half-life alone.
Sources
Every claim above traces to peer-reviewed literature indexed on PubMed, or to the published positions of the FDA, WADA and USADA:
- Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing — PubMed 40789979
- Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review — PubMed 40756949
- From Regeneration to Analgesia: The Role of BPC-157 in Tissue Repair and Pain Management — PubMed 41898733
- The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration — PubMed 21030672
- Gastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healing — PubMed 30915550
- Stable Gastric Pentadecapeptide BPC 157 and Wound Healing — PubMed 34267654
- Stable gastric pentadecapeptide BPC 157: novel therapy in gastrointestinal tract — PubMed 21548867
- Protective effects of pentadecapeptide BPC 157 on gastric ulcer in rats — PubMed 15052688
- Toxicity by NSAIDs. Counteraction by stable gastric pentadecapeptide BPC 157 — PubMed 22950504
- Injectable Therapeutic Peptides — An Adjunct to Regenerative Medicine and Sports Performance? — PubMed 39265666
- Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians — PubMed 41476424
- Oral delivery of peptide drugs: barriers and developments — PubMed 15984901
- Thymosin beta 4: a novel corneal wound healing and anti-inflammatory agent — PubMed 19668473
- The human tri-peptide GHK and tissue remodeling — PubMed 18644225
- The efficacy of thymosin alpha-1 as immunomodulatory treatment for sepsis — PubMed 27633969
- Drug Trials (overview of clinical trial phases) — PubMed 31536202
Regulatory positions cited: the USADA advisory on BPC-157 and WADA's Prohibited List class S0; the FDA's human drug compounding program and its Pharmacy Compounding Advisory Committee docket for the July 2026 meeting.